Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 901–1,000 of 1,000
McQuarter, A. A., Cruz, J., Yamauchi, C. R., Chouchen, M., Carter, C. S., Webb, T. J., & Khan, S. (2026) · Current Oncology · doi:10.3390/curroncol33010059 · Cited by 8
Behrens, D., Pfohl, U., Conrad, T., Becker, M., Brzezicha, B., Büttner, B., Wagner, S., Hallas, C., Lawlor, R. T., Khazak, V., et al. (2023) · Cancers · doi:10.3390/cancers15245753 · Cited by 8
“Several studies have shown that a depletion in FAP-positive CAFs restricted tumor growth by enhancing antitumor immunity, which occurs through multiple mechanisms, including loss of immunosuppressive effects of stromal cells or enhancement of tumor survival [83,84].”
BackgroundAl-Obaidi, I., Sandhu, C., Qureshi, B. J., & Seymour, L. W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39204 · Cited by 8
“This overall promotes immunosuppression [19], angiogenesis and metastasis, countering OV effects.”
BackgroundIdentification of Breast Cancer Subtypes Based on Gene Expression Profiles in Breast Cancer Stroma
Uddin, M. N., & Wang, X. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.04.001 · Cited by 9
Armando, F., Mazzola, F., Ferrari, L., & Corradi, A. (2022) · Veterinary Sciences · doi:10.3390/vetsci10010019 · Cited by 10
“Within the TME, different immunosuppressor cells can be found, including myeloid-derived suppressor cells (MDSCs) [176,177], cancer-associated fibroblasts (CAFs) [178,179], tumor-associated macrophages (TAMs) [180,181] and Treg lymphocytes [182,183], producing immunosuppressive mediators such as IL-10, TGF-β, VEGF, PG…”
Ai, W., Liu, T., Lv, C., Feng, X., & Wang, Q. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0088 · Cited by 8
Ge, W., Yue, M., Wang, Y., Wang, Y., Xue, S., Shentu, D., Mao, T., Zhang, X., Xu, H., Li, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010156 · Cited by 8
Cancer-associated fibroblasts in neoadjuvant setting for solid cancers
Gu, Y., Chen, Q., Yin, H., Zeng, M., Gao, S., & Wang, X. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104226 · Cited by 8
Investigation of the phototoxic effect of ZnO nanorods on fibroblasts and melanoma human cells
Kishwar, S., Siddique, M., Israr, M. Q., Nur, O., Willander, M., & Öllinger, K. M. (2014) · Laser Physics Letters · doi:10.1088/1612-2011/11/11/115606 · Cited by 9
Flow Cytometric Identification of Fibrocytes in Scleroderma Lung Disease
Russell, T. M., Herzog, E. L., & Bucala, R. (2012) · Methods in molecular biology · doi:10.1007/978-1-60761-720-4_16 · Cited by 9
McAndrews, K. M., Mahadevan, K. K., & Kalluri, R. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041411 · Cited by 8
Lee, M., Yoon, Y.-J., Lee, J. Y., Hwang, M., Park, S., Lee, M. H., Um, S., Cho, B. C., Rheey, J., Sato, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29214-9 · Cited by 10
“4B, C) 29–31 , with such differentiation being absent in BVO monocultures.”
Fibroblasts as Immunological Sentinels in Cutaneous Inflammation: A Review
Quan, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020556 · Cited by 7
Shen, Y., Sun, Y., Li, X., Wang, Y., Huang, T., Li, T., Zhu, Y.-Z., Hu, L., & Xu, C. S. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2025.189 · Cited by 7
Zhang, G., Shu, Z., Yu, J. Q., Li, J., Yi, P., Wu, B., Deng, D., Yan, S., Li, Y., Ren, D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341209 · Cited by 7
Santerre, J. P., Yang, Y., Du, Z., Wang, W., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492323 · Cited by 7
Bahri, M., Al‐Adhami, T., Demirel, E., Sarkar, J., Feehan, K. T., Anstee, J. E., Cheung, T. S., Sosnowska, D., Woodman, C. A., Macmorland, W., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads3085 · Cited by 7
Self-citationZhang, L., Ying, W., Sheng, Z., Lv, L., Gao, J., Xue, Y., & Liu, L. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.114859 · Cited by 7
Cancer-associated fibroblasts: challenges and opportunities
Tavana, H., & Luker, G. D. (2023) · Oncotarget · doi:10.18632/oncotarget.28385 · Cited by 7
Batra, H. V., Ding, Q., Pandurengan, R. K., Ibarguen, H. P., Rabassedas, N. B., Şahin, A. A., Wistuba, I. I., Parra, E. R., & Raso, M. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1281650 · Cited by 7
Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression
Basso, D. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000278 · Cited by 7
“Fibroblast activation protein (FAP-α) Suppresses effector T cells [135]”
Pang, T., Wang, X., Gao, J., Chen, W., Shen, X. J., Nie, M. M., Luo, T., Yin, K., Fang, G.-E., Wang, K. X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20273 · Cited by 7
“FAP was also specifically expressed in CAFs [14, 29] and was associated with cell invasion, growth and angiogenesis in tumors [30].”
BackgroundKim, S., Yeo, M., Kim, J.-S., Kim, J., & Kim, K. (2021) · Journal of Cancer · doi:10.7150/jca.64082 · Cited by 7
“FAPα, a type II membrane protein belonging to the serine protease family, has been known to be is up-regulated in activated fibroblasts of healing wounds, fetal mesenchymal tissues, and the tumor stroma of epithelial cancers [60, 61].”
BackgroundProfiling the Immune Stromal Interface in Breast Cancer and Its Potential for Clinical Impact
Irshad, S., Grigoriadis, A. E., Lawler, K., Ng, T., & Tutt, A. N. J. (2012) · Breast Care · doi:10.1159/000341529 · Cited by 7
Genetic Mouse Models of Cancer
Winslow, M. M., & Jacks, T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00009-3 · Cited by 7
Role of cancer-associated fibroblasts in tumor microenvironment
Mir, M. A., Sofi, S., & Aisha, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00002-6 · Cited by 6
Chen, J., Ma, P., Xu, J., Zang, M., & Li, W. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03770 · Cited by 6
Guan, X., Shen, Y., Zhao, C., Li, X., Li, X., Lü, D., Wang, L., Liu, L., Wu, S., Huang, B., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500176 · Cited by 6
Targeting TAMs & CAFs in melanoma: New approaches to tumor microenvironment therapy
Mayasin, Y. P., Osinnikova, M. N., Osadchaya, D., Dmitrienko, V., Gorodilova, A. V., Kharisova, C. B., Kitaeva, K. V., Filin, I. Y., Solovyeva, V., & Rizvanov, A. A. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.064677 · Cited by 7
Nørregaard, K. S., Larsen, I. M. E., Jürgensen, H. J., Blomquist, M. H., Çakılkaya, P., Metrangolo, V., Perlado, A. M., Krigslund, O., Gårdsvoll, H., Poulsen, T. T., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0051 · Cited by 6
Hernández‐Peralta, P., Chacón‐Salinas, R., Gracia‐Mora, I., Soldevila, G., Moreno, J. G., & Cobos-Marín, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-65960-y · Cited by 6
“The dominance of the M2 profile translates into a decrease in the M1 profile that produces IFN-γ, nitric oxide, IL-12, and IL-18 45 .”
BackgroundWei, J., Lu, Y., Lu, J., Wang, Z., Yan, Y., Liang, B., Qian, S., Ni, J., Yang, Y., Huang, S., et al. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1476092 · Cited by 7
Apte, M. V., Pirola, R. C., & Wilson, J. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00016-6 · Cited by 7
Blyth, K., Morton, J. P., & Sansom, O. J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.009 · Cited by 7
“Thus far however few therapeutics have worked in this model, seemingly owing to the inability of conventional therapeutics to access the tumour [4 ,5].”
BackgroundIn situ functional cell phenotyping reveals microdomain networks in colorectal cancer recurrence
Furman, S. A., Stern, A. M., Uttam, S., Taylor, D. L., Pullara, F., & Chennubhotla, S. C. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100072 · Cited by 7
“…(Augustin et al., 2016; Bienz and Clevers, 2000; de Jaeghere et al., 2019; Dienstmann et al., 2017; Galluzzi et al., 2019; Grasso et al., 2018; Kraman et al., 2010; Naito et al., 1998; Pai et al., 2017; Spranger and Gajewski, 2015, 2018; Turley et al., 2015; Wong et al., 2019; Yaeger et al.,…”
The application of FAPI-targeted theranostics in pancreatic cancer: a narrative review
Liu, M., Hacker, M., Huo, L., & Li, X. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000090 · Cited by 6
Radiation-induced FAP + fibroblasts are involved in keloid recurrence after radiotherapy
Gao, Y. H., Hou, X., Dai, Y., Yang, T., & Chen, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.957363 · Cited by 6
“Moreover, a similar result from a transplanted tumor model demonstrated that FAP + stromal cells could facilitate immunosuppression via ablation of T cell antitumor activity (Kraman et al., 2010).”
ResultDipeptidyl Peptidase-IV and Related Proteases in Brain Tumors
Bušek, P., & Šedo, A. (2013) · InTech eBooks · doi:10.5772/53888 · Cited by 6
Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances
Keenan, B. P., Jaffee, E. M., & Armstrong, T. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0011 · Cited by 6
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia
Schnaiter, A., & Stilgenbauer, S. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711406769 · Cited by 6
“It inhibits the activation of fibroblast activation protein (FAP) which is essential for development, growth and metastasis of epithelial tumours [Kraman et al. 2010] but is also found in the stroma of lymphoid tissue.”
BackgroundFascin as a useful marker for cancer-associated fibroblasts in invasive lung adenocarcinoma
Yamada, Y., Kurata, A., Fujita, K., & Kuroda, M. (2021) · Medicine · doi:10.1097/md.0000000000027162 · Cited by 6
Fibroblast Activation Protein Specific Optical Imaging in Non-Small Cell Lung Cancer
Mathieson, L., O’Connor, R. A., Stewart, H. L., Shaw, P. A., Dhaliwal, K., Williams, G. O. S., Megía-Fernández, A., & Akram, A. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834350 · Cited by 6
A Theranostic Approach for CAR-T Cell Therapy
Weber, W., Varasteh, Z., Fritschle, K., & Morath, V. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2565 · Cited by 6
Brewer, G., Savage, P., Fortier, A.-M., Zhao, H., Pacis, A., Wang, Y.-C., Zuo, D., de Nóbrega, M., Pedersen, A., de Camps, C. C., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.04.061 · Cited by 5
Chen, X., Liu, Q., Cen, Y., Yu, B., Liu, Y., Zhang, W., Li, J., Tang, Y., Miao, Y., Guo, N., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202423200 · Cited by 10
Noguchi, S., Yamamoto, T., Nakanishi, Y., Matsumoto, T., Shimada, Y., Shindo, K., Nakata, K., Fujita, N., Ishigami, K., Nakamura, M., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100865 · Cited by 5
Syrnioti, A., Timotheadou, E. T., Papadopoulos, V. N., Syrnioti, G., & Κoletsa, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211211 · Cited by 5
Fan, M., Guo, X., Liu, G., Tian, C., Zhao, J., & Chen, Y. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006210 · Cited by 5
Alsibai, K. D. (2014) · Journal of Cancer Prevention & Current Research · doi:10.15406/jcpcr.2014.01.00006 · Cited by 5
Pacheco‐Torres, J., Sharma, R. K., Mironchik, Y., Wildes, F. B., Brennen, W. N., Artemov, D., Krishnamachary, B., & Bhujwalla, Z. M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354076 · Cited by 6
Collagen 1 Fiber Volume Predicts for Recurrence of Stage 1 Non-Small Cell Lung Cancer
Kakkad, S. M., Krishnamachary, B., Fackche, N. T., Garner, M. S., Brock, M. V., Huang, P., & Bhujwalla, Z. M. (2024) · Tomography · doi:10.3390/tomography10070083 · Cited by 5
“CAF subtypes have been associated with establishing an immunosuppressive tumor microenvironment [36–38], and promoting tumor invasion and metastasis [34,35,39,40].”
BackgroundLi, J., Lei, T., Ouyang, W., Ye, Z., Li, L., Li, G., & Liu, H. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158308 · Cited by 5
What can rheumatologists learn from translational cancer therapy?
Sherlock, J. P., Filer, A. D., Isaacs, J. D., & Buckley, C. D. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4203 · Cited by 5
“Given the success of agents targeting cancer-associated stromal cells in general and the fi broblast markers FAP [46] and CD248 [47] in particular, targeting similar pathogenic stromal cells in immune-mediated infl ammation has already shown [48], and is likely to continue to show, considerable promise.”
BackgroundModulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
Li, X., Luo, X., & Hu, S. (2023) · Bioimpacts · doi:10.34172/bi.2023.24166 · Cited by 8
Tadokoro, Y., Takeda, D., Murakami, A., Yatagai, N., Saito, I., Arimoto, S., Kakei, Y., Akashi, M., & Hasegawa, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290357 · Cited by 5
“integral membrane protein, is highly expressed in fibroblasts and pericytes and is active in wound healing, fibrosis, and extracellular matrix degradation [29, 30].”
BackgroundMetabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications
Gong, R., Hu, Y., Yu, Q., Fang, L., & Ren, H. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000146 · Cited by 6
“[16,17] 20] The thick stroma promotes the collapse of the tumor vasculature, which generates a hypoxic and nutrient-poor microenvironment.”
BackgroundAlfred, M. O., Ochola, L. B., Okeyo, K. O., Bae, E., Ogongo, P., Odongo, D., Njaanake, K. H., & Robinson, J. P. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1521265 · Cited by 5
Johnson, M. (2013) · Materials and Methods · doi:10.13070/mm.en.3.158 · Cited by 5
Cancer makes new friends with old tricks
Dazzi, F. (2013) · Blood · doi:10.1182/blood-2013-06-509620 · Cited by 5
“It is also unknown whether fibrocytes at the tumor site exhibit the same characteristics of the circulating fibrocytes.(6) A further similarity with the other suppressors is the mechanism of action.”
BackgroundExplaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities
Fearon, D. T. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030783 · Cited by 6
“…of tumor growth; the cancer-associated fibroblasts were the major, intratumoral cellular source of CXCL12, the ligand for CXCR4; and the PDAC cancer cells appeared to be “coated” with the chemokine, despite the absence of CXCL12 mRNA in these cells (Kraman et al. 2010; Feig et al. 2013).”
BackgroundSelf-citationLin, W., Huang, W., Mei, S.-Q., Lu, X., Zheng, J., Wang, H., Zheng, L., & Zhang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-61951-3 · Cited by 5
Kunitomo, T., Noma, K., Nishiwaki, N., Nishimura, S., Takeda, Y., Matsumoto, H., Tatsuya, T., Kawasaki, K., Akai, M., Maeda, N., et al. (2025) · Cancers · doi:10.3390/cancers17203351 · Cited by 4
“To resolve this problem, we adopted a simplified approach involving a single-stain IHC evaluation of FAP + CAFs, which are widely recognized as a tumor-promoting and immunosuppressive subtype of CAFs closely associated with tumor progression and poor clinical outcomes [19,20,43–45].”
Armstrong, A., van der Plancke, G., Nishiguchi, S., Salas‐Benito, D., Bouffard, A. A., Goncalves, S., Merce, A. T., Kelly, C., Birocchi, F., Park, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2907 · Cited by 5
Sun, S., Zhao, P., Wang, C., Du, J., Zhang, T., He, X., Zhibo, Z., Li, N., & Zhou, R. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1668583 · Cited by 5
“…protein (FAP) is another surface marker of CAFs, the depletion of which leads to acute post-ischemia cancer hypoxic necrosis through the prothrombotic effects of IFN-γ and tumor necrosis factor-α (TNF-α) in Lewis lung carcinoma 2 expressing ovalbumin (LL2/OVA) tumors (Kraman et al., 2010).”
Kansestani, A. N., Zare, M. E., & Zhang, J. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01129-7 · Cited by 4
Kong, X., Cheng, R., Zhang, W., Lu, Y., Kan, Y., Fang, Y., Gao, J., Wang, J., & Hwang, K. C. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101392 · Cited by 4
Heilijgers, F., Bakker, M.-C., van Hest, B., Franken, I. A., Speetjens, F. M., Peeters, K. C. M. J., Roodhart, J. M. L., & Mesker, W. E. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01220-5 · Cited by 6
“TGF-β signaling can induce CAF subtypes, which undergo dynamic changes in response to anticancer treatment, contributing to poor outcomes and resistance to therapy [94–96].”
Zhang, Z., Rong, W., & Chen, L. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04567-z · Cited by 6
Mimicking the immunosuppressive impact of fibroblasts in a 3D multicellular spheroid model
Grotz, M., van Gijzel, L., Bitsch, P., Carrara, S. C., Kolmar, H., & Garg, S. (2024) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2024.1427407 · Cited by 4
Li, Q., & Liu, H. (2025) · Biomedicines · doi:10.3390/biomedicines13040826 · Cited by 5
Zhang, Q., Tan, Y., Liang, Q., Gu, L., Shi, Y. X., Huang, Y., Li, X., Qi, J., Peng, C., Wang, H., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.07.010 · Cited by 6
High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer
Hu, S., Liu, Q., & Huang, Z. (2017) · Biomedical Research-tokyo · Cited by 4
Morphological Transformation of Self‐Assembled Peptide Nanostructures for Bioimaging Applications
Xu, Y., Jiang, Q., Sun, X., & Liang, G. (2023) · Analysis & Sensing · doi:10.1002/anse.202300039 · Cited by 4
A Systemic Review of Clinical Trials on Dendritic-Cells Based Vaccine Against Malignant Glioma
Tang, X. (2015) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000222 · Cited by 4
Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas
Sun, L., Schroeder, M. C., Hagemann, I. S., Pfeifer, J. D., Schwarz, J. K., Grigsby, P. W., Markovina, S. T., & Lin, A. J. (2022) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000853 · Cited by 4
“05 II 14 (20) 7 (50) IIIB 6 (8) 3 (50) IIIC1 22 (31) 13 (59) IIIC2 10 (14) 8 (80) IV 3 (4) 2 (67) SUVmax SUVmax > 11.”
BackgroundGaretto, S., Sardi, C., Morone, D., & Kallikourdis, M. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-42223-7_7 · Cited by 4
Nuklearmedizinische Theranostik: Update Nuklearmedizin 2021
Eiber, M., Kratochwil, C., Lapa, C., & Brenner, W. (2021) · Der Onkologe · doi:10.1007/s00761-021-00956-1 · Cited by 4
“d) FAP-positive Tumorfibroblasten unterdrücken die gegen den Tumor gerichtete Immunreaktion [20].”
BackgroundInfluentialFibroblast activation protein, a potential diagnostic and therapeutic target for cancer—reply
Tchou, J. C., & Conejo-Garcia, J. R. (2014) · Human Pathology · doi:10.1016/j.humpath.2013.11.022 · Cited by 4
Song, M., Xie, H., Liu, W., Zhao, M., Deng, Z., Zhang, L., Liu, H., Huang, Y., Li, H., Ren, Y., et al. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3455 · Cited by 3
“Kraman et al.(24) found that the depletion of FAP-expressing cells caused rapid hypoxic necrosis in both cancer and stromal cells in immunogenic tumors by a process involving interferon-γ.”
BackgroundLiu, T., Zhang, D., Wang, X., Li, J., Zhang, H., Tang, K., & Wang, L. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167856 · Cited by 3
Zu, P., & Yu, Z. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1761070 · Cited by 3
“…share similar characteristics; therefore, whether some subsets of CAFs belong to the same population is debated, and model-specific data have been interpreted by different laboratories (Feig et al., 2013; Kieffer et al., 2020; Kraman et al., 2010; Ohlund et al., 2014; Puram et al., 2017).”
Sharma, S. R. K., Saha, S., Arora, S., Ahlawa, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100012 · Cited by 3
Sugrue, T., Calvo‐Asensio, I., & Ceredig, R. (2016) · Wiley eBooks · doi:10.1002/9781118907474.ch27 · Cited by 4
Cardio-oncology imaging tools at the translational interface
Yaros, K., Eksi, B., Chandra, A., Agusala, K., Lehmann, L., & Zaha, V. G. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.012 · Cited by 3
Caron, J. M., Han, X., Lary, C. W., Sathyanarayana, P., Remick, S. C., Ernstoff, M. S., Herlyn, M., & Brooks, P. C. (2023) · Oncology Reports · doi:10.3892/or.2023.8481 · Cited by 3
Sosnowska, D., Cheung, T. S., Sarkar, J., Opzoomer, J. W., Feehan, K. T., Anstee, J. E., Woodman, C. A., Keddar, M. R., Clayton, K., Ali, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.191017 · Cited by 3
Self-citationOvarian Cancers: Their Varied Origins and Pathologically Implicated Microenvironment
Sun, Y., & Auersperg, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00032-7 · Cited by 3
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Kaur, J., Singh, P., Enzler, T., & Sahai, V. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1905795 · Cited by 3
Zhu, Z., Shi, L., Dong, Y., Zhang, Y., Yang, F., Wei, J., Huo, M., Li, P., & Liu, X. (2022) · PubMed · Cited by 4
Gong, Y., Kang, J., Wang, M., Hayati, F., Rahim, S. S. S. A., & Goh, L. P. W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2312599 · Cited by 5
“36 FAP and its secretions can hinder the immune response through diverse mechanisms.”
BackgroundChemokine receptors and their ligands in breast cancer: The key roles in progression and metastasis
Valdivia‐Silva, J., & Chinney-Herrera, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.07.002 · Cited by 3
Novel Insights Into the Role of Inflammation in Promoting Breast Cancer Development
Valdivia‐Silva, J., Franco‐Barraza, J., Cukierman, E., & Garcia-Zepe, E. A. (2011) · InTech eBooks · doi:10.5772/21699 · Cited by 3
“Moreover, it has been shown that CAFs effectively suppress anti-tumor inflammation while, at the same time, maintaining acute inflammatory (pro-tumor) conditions (Kraman et al., 2010).”
Hussain, M., Shah, Z., Abbas, N., Javeed, A., Mukhtar, M. M., & Zhang, J. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.11.031 · Cited by 3
“However, the tumor microenvironment privileges a variety of immune-suppressive regulators, rather than immune effectors, particularly including; tumor-associated macrophages and fibroblasts [14], T regulatory cells (Tregs) and myeloidderived suppressor cells (MDSCs) [15], and various immunoinhibitory mediators such as…”
BackgroundChambers, C. V. (2011) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2011.07.008 · Cited by 3
Chen, M., Xiang, R., Wen, Y., Xu, G., Wang, C., Luo, S., Yin, T., Wei, X., Shao, B., Liu, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72743-8 · Cited by 3
Zhu, Y., Xiang, M., Brulois, K., Lazarus, N. H., Pan, J., & Butcher, E. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4538031/v1 · Cited by 6
Tang, D., Gao, J., & Wang, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu165.29 · Cited by 2
Dong, S., Chen, X., Li, X., Wang, Y., Huang, Q., Li, Y., Jin, J., Zhu, X., Zhong, Y., Cai, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509087 · Cited by 6
Wilms Tumor 1–Expressing Stromal Cells Promote Pancreatic Cancer Progression
Bischoff, A. C., Brown, K. L., Opsahl, E. L. L., Watkoske, H. R., Espinoza, C. E., Okoye, J. O., Olivei, A. C., Green, L. M., Rai, R., The, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1014 · Cited by 2
Li, Y., Di, X., Chen, J., Wei, J., Li, T., Wang, K., Liao, B., & Luo, D. (2025) · MedComm – Oncology · doi:10.1002/mog2.70048 · Cited by 5
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.